Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Arcalyst | rilonacept | Kiniksa Pharmaceuticals | N-125249 RX | 2008-02-27 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
arcalyst | Biologic Licensing Application | 2025-03-07 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
inborn genetic diseases | EFO_0000508 | D030342 | — |
inflammation | MP_0001845 | D007249 | — |
Expiration | Code | ||
---|---|---|---|
rilonacept, Arcalyst, Kiniksa Pharmaceuticals (UK), Ltd. | |||
2028-03-18 | Orphan excl. |
Code | Description |
---|---|
J2793 | Injection, rilonacept, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | — | 1 | 1 | — | — | 2 |
Pericarditis | D010493 | EFO_0007427 | I30 | — | 1 | 1 | — | — | 2 |
Drug common name | Rilonacept |
INN | rilonacept |
Description | [653-glycine][human interleukin-1 receptor accessory protein-(1-339)-peptide (extracellular domain fragment) fusion protein with human type 1 interleukin-1 receptor-(5-316)-peptide (extracellular domain fragment) fusion protein with human immunoglobulin G1-(229 C-terminal residues)-peptide (Fc fragment)], (659-659':662-662')-bisdisulfide dimer |
Classification | Protein |
Drug class | receptor molecules or membrane ligands, natural, modified or modified: interleukin receptors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201830 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB06372 |
UNII ID | 8K80YB5GMG (ChemIDplus, GSRS) |